NEK2 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population of Raji B lymphocytes harboring a targeted disruption of the NEK2 gene. This loss-of-function model enables the investigation of NEK2-dependent processes without the constraints of clonal selection, providing a heterogeneous yet genetically defined background for studying centrosomal kinase activity in a lymphoma context. The polyclonal nature avoids single-clone artifacts while offering sufficient target-gene ablation for functional assays, making it a versatile tool for cancer researchers exploring mitotic regulation and tumor progression.
The parental Raji cell line is an EBV-positive Burkitt’s lymphoma B-cell model widely used to dissect B-cell malignancy biology. Derived from an aggressive non-Hodgkin lymphoma, Raji cells exhibit rapid proliferation, high transfection efficiency, and characteristic surface markers, rendering them suitable for studying oncogenic signaling, cell cycle dysregulation, and therapeutic responses. Their lymphoblastoid phenotype facilitates experiments in suspension culture, flow cytometry, and functional genomics, particularly in the context of hematopoietic cancers where NEK2 is frequently overexpressed.
NEK2 is a serine/threonine kinase critical for mitotic progression, localizing to centrosomes and kinetochores to drive centrosome separation, bipolar spindle assembly, and faithful chromosome segregation. Its expression is tightly controlled by the ubiquitin ligase APC/C-Cdh1 and is transcriptionally activated by E2F1 and FOXM1. Upstream activation by PLK1 primes NEK2 for phosphorylation of downstream targets, including ??-catenin (CTNNB1), the cohesion protector SGO1, the centrosomal linker protein C-Nap1 (CEP250), and the spindle assembly checkpoint component MAD1. Through these interactions, NEK2 integrates signals from the cell cycle machinery and the Hippo pathway, where it complexes with MST2 (STK3) and PPP1CC to modulate YAP activity. Dysregulated NEK2 activity consequently fuels genomic instability and aberrant Wnt/??-catenin signaling.
In the Raji B-lymphoma context, NEK2 knockout disrupts a kinase whose overexpression is linked to poor prognosis in hematological malignancies. By eliminating NEK2 function in an EBV-driven lymphoblastoid background, this model enables dissection of its contributions to centrosome amplification, checkpoint override, and drug resistance mechanisms often observed in aggressive lymphomas. The polyclonal population mirrors the genetic heterogeneity found in tumors, allowing assessment of NEK2 loss on proliferation rates, apoptosis induction, and sensitivity to chemotherapeutics like doxorubicin, while preserving the oncogenic Epstein?CBarr virus latency program inherent to Raji cells.
This polyclonal knockout cell pool is particularly suited for studies requiring stable NEK2 depletion in large-scale functional screens, cell cycle analysis, and signaling interrogation. Typical assays include Western blotting to confirm NEK2 ablation and monitor downstream targets such as ??-catenin and CEP55; immunofluorescence staining for centrosomal markers like ??-tubulin to assess mitotic defects; propidium iodide-based flow cytometry for cell cycle distribution; and MTS assays to measure proliferation. Additional applications involve Annexin V apoptosis detection, Transwell migration assays, and doxorubicin sensitivity profiling, making the product valuable for elucidating NEK2 roles in lymphoma progression and drug resistance. For further assistance, please contact Ascent Research.
